Media Release
- Hands-on booth demonstrations of the UNITY platform showcase next-generation surgical advancements
- Recent innovations also include Clareon PanOptix Pro intraocular lenses and Valeda PBM for AMD, reflecting the breadth of innovation across Alcon's portfolio
FORT WORTH, October 5, 2026 — Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, will highlight its innovation portfolio at the 2026 American Academy of Ophthalmology (AAO) annual meeting, October 10-12 in New Orleans. Attendees visiting Alcon at Booth #1519 can explore hands-on demonstrations spanning cataract, retina, glaucoma and dry eye disease. Featured innovations include the UNITY® platform, highlighted by the new UNITY® M ophthalmic microscope, along with Clareon® PanOptix® Pro, Clareon® TruPlus® IOLs, Valeda™ Photobiomodulation (PBM) and Voyager™ DSLT.
"At AAO 2026, Alcon will demonstrate how innovation is redefining what's possible in eye care," said Sergio Duplan, President of the Americas at Alcon. "Attendees will experience firsthand how our portfolio is helping shape the future of eye care through technologies and clinical solutions that support eye care professionals every day."
UNITY Booth Demonstrations Provide a Firsthand Look at Alcon's Surgical Platform
The UNITY platform will anchor Alcon's AAO presence. Attendees can participate in private demonstrations of both configurations: the UNITY VCS combined console and the UNITY CS standalone cataract system. The recently launched UNITY® M microscope, a premium surgical microscope that delivers precise control for ophthalmic surgeons, will also be featured. Together, these experiences provide a firsthand look at how connected surgical technologies support visualization, workflow efficiency and surgical performance. Alcon experts will be available for one-on-one discussions and product demonstrations throughout the meeting.
Recent Innovations Demonstrate Alcon's Broad Eye Care Portfolio
Alcon's booth will also feature demonstrations highlighting several of the company's newest innovations. In cataract surgery, attendees can learn more about Clareon PanOptix Pro, the latest evolution of the world's leading trifocal family, as well as Clareon TruPlus IOLs, Alcon's next-generation monofocal and toric IOL platform designed to build on the performance of the Clareon family.
In retina, attendees can explore Valeda PBM, the first and only FDA-authorized treatment for patients with early and intermediate dry age-related macular degeneration (AMD), through dedicated technology demonstrations.1
In glaucoma, Alcon will showcase Voyager DSLT, an innovative first-line glaucoma treatment option powered by automated SureTrac eye-tracking technology, which precisely delivers laser pulses through the limbus to the trabecular meshwork.2
In addition to its surgical portfolio, Alcon will highlight TRYPTYR® (acoltremon ophthalmic solution) 0.003%, a prescription treatment option for the millions of patients affected by dry eye disease (DED). As the first neuromodulator eye drop that can rapidly increase natural tear production as early as day one, TRYPTYR represents a novel approach to DED management.3-7 Attendees can learn more about this innovation, including its first-in-class mechanism of action, by visiting Alcon at booth #1519.
For more information about Alcon's presence at AAO 2026, including demonstrations, presentations and featured innovations, visit www.MyAlconatAAO.com.
About Alcon
Alcon helps people see brilliantly. As the global leader in eye care with a heritage spanning over 75 years, we offer the broadest portfolio of products to enhance sight and improve people’s lives. Our Surgical and Vision Care products touch the lives of more than 260 million people in over 140 countries and territories each year living with conditions like cataracts, glaucoma, retinal diseases and refractive errors. Our more than 25,000 associates are enhancing the quality of life through innovative products, partnerships with Eye Care Professionals and programs that advance access to quality eye care. Learn more at www.alcon.com.
Connect with us on Facebook and LinkedIn.
About TRYPTYR® (acoltremon ophthalmic solution) 0.003%
INDICATIONS AND USAGE
TRYPTYR® (acoltremon ophthalmic solution) 0.003% is indicated for the treatment of the signs and symptoms of dry eye disease (DED).
IMPORTANT SAFETY INFORMATION
Warnings and Precautions
Potential for Eye Injury and Contamination: To avoid the potential for eye injury and contamination, advise patients not to touch the vial tip to the eye or other surfaces.
Use with Contact Lenses: TRYPTYR should not be administered while wearing contact lenses. If contact lenses are worn, they should be removed prior to administration of the solution. Lenses may be reinserted 15 minutes following administration of TRYPTYR.
Adverse Reactions
In clinical trials, the most common adverse reaction was instillation site pain (50%).
Please click here for the TRYPTYR Full Prescribing Information.
About Valeda® PBM
The Valeda Light Delivery System improves visual acuity in patients with best-corrected visual acuity of 20/32 through 20/70 and who have dry age-related macular degeneration (AMD) characterized by: 1. The presence of at least 3 medium drusen (> 63 μm and ≤ 125 μm in diameter), or large drusen (> 125 μm in diameter), or non-central geographic atrophy, and 2. The absence of neovascular maculopathy or central-involving geographic atrophy. Do not treat patients with Valeda if they have any known photosensitivity to yellow light, red light, or near-infrared radiation (NIR), have a history of light-activated central nervous system disorders (e.g., epilepsy, migraine), or within 30 days of using photosensitizing agents. Treatment benefit may not persist significantly after treatment is stopped. No significant data on the safety and effectiveness for more frequent or extended treatments beyond described in operator’s manual.
About UNITY® VCS and CS
The UNITY® VCS (Vitreoretinal Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e., phacoemulsification and removal of cataracts) and posterior segment (i.e., vitreoretinal) ophthalmic surgery. The UNITY® CS (Cataract System) console, when used with compatible devices, is indicated for use during anterior segment (i.e., phacoemulsification and removal of cataracts) ophthalmic surgery. Refer to the Directions for Use for the accessories/consumables and User Manual for a complete listing of indications, warnings, cautions and notes.
About UNITY® M
UNITY® M is the latest ophthalmic microscope available by Alcon. As with all ophthalmic microscopes, exposure during aphakia should be limited to reduce the risk of damage. During aphakia and at maximum illumination intensity, limit exposure to red reflex light to no more than 9.6 minutes.
About Clareon® PanOptix® Pro
The Clareon PanOptix Pro Trifocal IOL is a type of multifocal IOL used to focus images clearly onto the back of your eye (retina) to allow clear vision after the cataract removal. In addition, the center of the Clareon PanOptix Pro Trifocal IOL allows for better near (reading) vision and intermediate (computer work) vision versus what a monofocal lens would provide. Potential Side Effects: Due to the design of multifocal IOLs, there are some side effects that can be associated with the Clareon PanOptix Pro Trifocal IOL models. These may be worse than with a monofocal IOL, including visual disturbances such as glare, rings around lights, starbursts (rays around light sources), and reduced contrast sensitivity (decreased ability to distinguish objects from their background, especially in dim lighting). These side effects may make it more difficult to see while driving at night or completing tasks in low lighting conditions such as at night or in fog or in a dimly lit room after surgery, as compared to before surgery.
References
- Valeda US Instructions for Use.
- Voyager DSLT Instructions for Use.
- TRYPTYR® U.S. FDA Prescribing Information. 2025.
- Restasis. Prescribing Information. Allergan; 2012. Accessed July 8, 2024. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/050790s020lbl.pdf.
- Xiidra. Prescribing Information. Bausch & Lomb; 2020. Accessed September 10, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/208073s005lbl.pdf
- Tyrvaya. Prescribing Information. Oyster Point Pharmaceuticals; 2024. Accessed January 16, 2025. https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/213978s000lbl.pdf
- Miebo. Prescribing Information. Bausch & Lomb; 2023. Accessed June 26, 2023. https://www.accessdata.fda.gov/drugsatfda_docs/label/2023/216675s000lbl.pdf
Media Relations
Kevin Nicoletti
+ 1 817 913 3461 (Fort Worth)
[email protected]
Investor Relations
Daniel Cravens
+ 1 817 615 2789 (Fort Worth)
[email protected]